Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epithelioid sarcoma (ES) is an aggressive, ultra-rare soft-tissue sarcoma characterized by SMARCB1/INI1 deficiency.
• This deficiency elevates EZH2 expression, a key factor in gene silencing via H3K27me3 methylation.
• Elevated EZH2 drives cancer cell proliferation in specific sarcoma subtypes.

Purpose of the Study:

• To evaluate tazemetostat, an EZH2 inhibitor, as a treatment for advanced epithelioid sarcoma.
• To assess the efficacy of tazemetostat in patients with metastatic or unresectable ES.

Main Methods:

• A single-arm, Phase II basket study was conducted.
• Patients aged 16 years and older with advanced or metastatic ES were enrolled.
• Tazemetostat was administered orally as a treatment.

Main Results:

• Tazemetostat demonstrated positive results in treating patients with advanced epithelioid sarcoma.
• The drug is approved for patients with metastatic or advanced ES ineligible for complete resection.
• Further research is needed to identify clinical and molecular predictors of response.

Conclusions:

• Tazemetostat represents a novel therapeutic option for epithelioid sarcoma patients.
• The drug's mechanism involves inhibiting EZH2 and reducing H3K27 methylation.
• Ongoing investigations explore combinations of tazemetostat with chemotherapy and immunotherapy.